Overview

Pyrotinib, LEtrozole And SHR6390 in Subjects With dUal-Receptor Positive(ER+/HER2+) Advanced Breast Cancer: a muLti-center phasE Ib/II Study

Status:
Recruiting

Trial end date:
2022-12-12

Target enrollment:

Participant gender:

Summary

This is a single-center Ib / II study of triple targeted drug combination (aromatase inhibitor letrozole，novel HER2-targeted small molecule inhibitor pyrotinib and CDK4/6 inhibitor SHR6390) as a first or second line of therapy in patients with relapsed/metastatic hormone receptor positive and HER2-positive breast cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Fudan University

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Aromatase Inhibitors
Letrozole